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Dr Gregory Fontana (Los Angeles, Calif). Dr Bleiziffer, your
program in Munich is unique in that this is one of the largest TAVI
experiences in the world but includes both the balloon-expandable
and self-expanding devices, and, arguably, the most surgeon-
driven program that I am aware of. Drs. Bleiziffer and Lange
work as surgeons with all access approaches along with their car-
diologists as primary operators and should serve as a model for
other surgical programs.
We have limited data available on 2-year clinical and echocar-
diography follow-up. The data are critical to our development of
guidelines for TAVI indications. These are truly excellent results,
especially considering the series represent the initial experience
with first-generation devices and represent multiple access tech-
niques. I have 2 questions for you.
The first one is about durability. Ten of the patients had mean
gradients greater than 20 mm Hg in follow-up, and many more
had an aortic valve area less than 1.2 cm2. Were you able to iden-
tify any leaflet pathology by echocardiography or evidence of
early degeneration, and if so, did the porcine or bovine tissue per-
form differently?
Dr Bleiziffer.What I have in mind is that these small valve or-
ifice areas are somehow difficult to interpret, we think, becauseery c February 2012
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a transcatheter bioprosthesis. The most sensitive parameter for
EOA calculation in echocardiography is the LVOT diameter, and
it is unclear where should this be measured, below the stent, or
within the stent. There are no guidelines. What we do is we mea-
sure within the stent, and that might contribute as to why we have
slightly smaller EOAs than may be reported from other groups.We
think this is not clinically significant in terms of the very low gra-
dients we receive with catheter valves. So maybe these end point
definitions proposed by the VARC could also undergo some revi-
sion in the future.
Dr Fontana. So none of the valves that you looked at that
had these gradients (eg,>20 mm) had anything looking mor-
phologically abnormal? It was just a gradient, a physiologic
measurement?
Dr Bleiziffer. No, they did not look abnormal.
Dr Fontana. Second question. Despite your transfemoral-first
approach, your transapical and transfemoral survivals are similar,
when typically transapical carries a greater risk because of the ath-
erosclerotic burden, at least in the 30-day mortality rates in many
series. In addition, there were fewer strokes in the transapical
group, only 1, versus 14 in the transfemoral group. Have the results
of the first 227 patients influenced your algorithm for valve choice
or access strategy?
Dr Bleiziffer. Yes, it has. When patients have stroke in their
history, we would rather go for a transapical approach.
Dr Fontana. Thank you.
Dr Eric Manasse (Milano, Italy). Was the rate of readmission
during the first year of follow-up different between the cohort
of patients who had more than 1þ paravalvular regurgitation or
intra-aortic and those without regurgitation? Did you perform
autopsies in the patients who died in your area?
Dr Bleiziffer. To the first question, we did a subanalysis and
saw an increased mortality in patients who left the hospital with
a moderate or a higher grade of paravalvular regurgitation, but
these were only initial analyses, so we will have a closer look atThe Journal of Thoracic and Cathat in the future. And, no, I am not aware of autopsies that have
been performed.
Dr Manasse. Did you observe an ongoing event of strokes in
the late follow-up?
Dr Bleiziffer. Yes, but the stroke rate was low. It was 0.9% of
the patients after the postprocedural period, very low.
Dr Tufan Paker (Istanbul, Turkey). I would like to learn about
your preferred technique if the patient receiving TAVI has con-
comitant coronary artery disease. Do you deal with it at the
same time or is a second procedure done?
Dr Bleiziffer.We do it as a staged procedure. If there is any cor-
onary that needs intervention, we do it before the TAVI procedure,
becausewe think the rapid pacing that has to be done, at least for bal-
loonvalvuloplasty,would be a riskwith significant coronary stenosis.
Dr Paker. How do you explain cardiac reason for death dealing
with myocardial infarction? I mean, if you do the coronary pathol-
ogy at the same time, do you change the postoperative results?
Dr Bleiziffer. I don’t understand your question.
Dr Paker. When you look at your postoperative results, myo-
cardial infarction is one of the reasons for a cardiac nature death.
Dr Bleiziffer. Yes, but that was rare. There were some single
patients who had coronary occlusion during the procedure and
died of myocardial infarction, for example.
Dr Paker. Thank you.
Dr Leonard Girardi (New York, NY). I have 1 question for you.
On the curves that you presented out to 2 years, there were an ever-
increasing number of patients whowere no longer in NYHA class I
and an ever-increasing number of patients in II and III and even III
and IV. Have you taken a look at those patients and what are you
ascribing that change to, because you have so many patients in
III and IV to start, a very good outcome in the first 6 months, and
then it seems to be declining. Is there any reason for that?
Dr Bleiziffer. Of course, I don’t have any detailed data on that
with me, but those are elderly patients and they also have comor-
bidities, and, of course, their clinical state gets worse and within
years.rdiovascular Surgery c Volume 143, Number 2 317
